New diabetes pill study doesn’t dispel heart risk

This version of New Diabetes Pill Study Doesn T Dispel Heart Risk Flna1C9472647 - Health and Medicine | NBC News Clone was adapted by NBC News Clone to help readers digest key facts more efficiently.

The maker of the controversial diabetes pill Avandia on Tuesday published preliminary results of a study that the company claims show the drug does not raise heart risks. However, experts say the results are inconclusive and even seem to suggest more risk from the drug.

More people on Avandia suffered heart problems than those on other diabetes drugs — a bad sign even if the difference was so small that it could have occurred by chance alone, some doctors said.

“This study, which was designed to show the benefit of rosiglitazone (Avandia), if anything shows the opposite,” said Dr. David Nathan, chief of diabetes care at Massachusetts General Hospital.

He wrote an editorial accompanying the study, which was published online by the New England Journal of Medicine. A congressional panel is holding a hearing Wednesday on the drug’s risks and the response by the federal Food and Drug Administration, which has been criticized for being too lax about safety concerns.

The heart risk trend in patients on Avandia “is going in the wrong direction,” said Dr. Steven Nissen of the Cleveland Clinic. Two weeks ago, he published in the same medical journal an analysis of 42 studies on Avandia concluding that the drug raised the risk of heart attacks by 43 percent and possibly heart-related deaths as well.

Avandia’s maker, British-based GlaxoSmithKline PLC, has said its own similar analysis found a 31 percent greater risk. However, Glaxo officials have said that more definitive studies, such as the preliminary findings released Tuesday preliminary, did not show such risk.

“Overall, we feel these results are very reassuring,” said Dr. Murray Stewart, Glaxo’s vice president of clinical development, said during a telephone news conference on Tuesday.

More than 6 million people worldwide have taken the drug, sold as Avandia and Avandamet, since it came on the market eight years ago to help control blood sugar in people with the most common form of diabetes. About 1 million Americans use it now.

The new study involves 4,500 people at more than 150 medical centers around the world.

×
AdBlock Detected!
Please disable it to support our content.

Related Articles

Donald Trump Presidency Updates - Politics and Government | NBC News Clone | Inflation Rates 2025 Analysis - Business and Economy | NBC News Clone | Latest Vaccine Developments - Health and Medicine | NBC News Clone | Ukraine Russia Conflict Updates - World News | NBC News Clone | Openai Chatgpt News - Technology and Innovation | NBC News Clone | 2024 Paris Games Highlights - Sports and Recreation | NBC News Clone | Extreme Weather Events - Weather and Climate | NBC News Clone | Hollywood Updates - Entertainment and Celebrity | NBC News Clone | Government Transparency - Investigations and Analysis | NBC News Clone | Community Stories - Local News and Communities | NBC News Clone